Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride provides a source of potassium ions, which are essential for maintaining intracellular tonicity, nerve impulse conduction, muscle contraction, and acid-base balance. Sodium chloride provides sodium and chloride ions, which are necessary for maintaining extracellular fluid volume and osmolality.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
FDA-approved: Replacement therapy for potassium and sodium deficiencies, maintenance of electrolyte balance in parenteral nutrition, and as a source of electrolytes in intravenous fluids.,Off-label: Management of hypokalemia, correction of hyponatremia, and prevention of electrolyte imbalances in patients unable to take oral fluids.
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous infusion: 0.037% potassium chloride in 0.9% sodium chloride solution; rate not to exceed 10 m Eq/hour (or 10 mmol/hour) potassium; typical adult dose 20-40 m Eq per day, adjusted based on serum potassium levels.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Potassium: Not applicable as endogenous ion with tight homeostatic control; administered potassium distributes rapidly and is eliminated with a functional half-life of about 1-2 hours in the central compartment due to redistribution and renal excretion, but total body potassium turnover half-life is approximately 20-30 days. Sodium: Not applicable; administered sodium is rapidly equilibrated and renally regulated.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Potassium and sodium are not metabolized; they are excreted primarily by the kidneys. Potassium is also excreted in feces and sweat. Sodium is mainly excreted in urine under the regulation of aldosterone and other hormones.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal excretion of potassium is the primary route (approximately 90% of daily intake), with minimal fecal loss (about 10%). The sodium component is also predominantly renally excreted, with >99% of filtered sodium reabsorbed under normal conditions.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Potassium: Not significantly protein-bound (<1%). Sodium: Not significantly protein-bound (<1%).
Low protein binding; 0–11% bound, primarily to albumin.
Potassium: Total body water (approximately 0.5 L/kg) with 98% intracellular; Vd for extracellular potassium is about 0.2 L/kg. Sodium: Primarily extracellular fluid, Vd approximately 0.2-0.3 L/kg.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Intravenous: 100%.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
GFR 20-50 m L/min: reduce maintenance dose by 25-50%; GFR <20 m L/min: avoid use or use with extreme caution, dose reduction of 50-75% and frequent monitoring of serum potassium.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No specific dose adjustments for Child-Pugh class A, B, or C; however, monitor serum potassium closely due to potential metabolic disturbances.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Intravenous infusion: 0.2-0.5 m Eq/kg/hour (max 1 m Eq/kg/day) for maintenance; for replacement, 0.3-1 m Eq/kg/dose based on serum potassium deficit; rate not to exceed 0.5-1 m Eq/kg/hour.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Initiate at low end of adult dosing; monitor renal function and serum potassium more frequently due to age-related decline in renal function and increased risk of hyperkalemia.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
None
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Administration may cause hyperkalemia, especially in patients with renal impairment, or if given too rapidly. Hypernatremia may occur with excessive sodium administration. Use with caution in patients with heart failure, renal insufficiency, or conditions predisposing to fluid overload. Monitor serum electrolytes and fluid balance. Do not administer unless solution is clear and container is intact.
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hyperkalemia, hypernatremia, severe renal impairment with oliguria or anuria, uncompensated heart failure, metabolic alkalosis, and known hypersensitivity to any component.
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
Avoid high-potassium foods (e.g., bananas, oranges, spinach, potatoes, tomatoes) unless directed by your healthcare provider, as they may increase risk of hyperkalemia. Salt substitutes often contain potassium chloride and should be avoided.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER: Potassium chloride is a normal constituent of body fluids and is essential for cellular function. At physiological concentrations, no teratogenic effects are expected. However, hyperkalemia may occur with excessive administration, which can cause maternal cardiac arrhythmias and potentially fetal distress. No specific fetal malformations are associated with potassium chloride at replacement doses. First trimester: No known teratogenic risk with appropriate use. Second and third trimesters: Use cautiously to avoid hyperkalemia, which may affect fetal heart rate; monitor maternal serum potassium levels.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Potassium chloride is a normal component of breast milk at concentrations around 13 m Eq/L. Administration of potassium chloride injection does not significantly alter breast milk potassium levels. The M/P ratio is approximately 1.0, reflecting passive distribution. Use is considered compatible with breastfeeding; no adverse effects on nursing infants are anticipated when maternal serum potassium is maintained within the normal range.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Pregnancy induces a state of expanded extracellular fluid volume and increased renal blood flow, leading to enhanced clearance of potassium. However, potassium chloride dosing adjustments are generally not required in pregnancy unless the patient develops hypokalemia or hyperkalemia. Dose should be guided by serum potassium levels, which may be slightly lower in pregnancy due to dilutional effects. Avoid excessive potassium administration to prevent hyperkalemia, especially in patients with impaired renal function or preeclampsia.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
This solution is used for maintenance hydration and to correct or prevent hypokalemia. Monitor serum potassium levels and renal function. Do not administer undiluted; ensure compatibility with concurrent medications. Use with caution in patients with renal impairment, adrenal insufficiency, or digitalis toxicity. Rapid infusion may cause hyperkalemia and cardiac arrest. Maximum infusion rate: 10 m Eq/h (0.037% KCl = 5 m Eq/L).
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
This medication is a potassium supplement given through your vein to maintain normal potassium levels.,Tell your healthcare provider if you have kidney problems, heart disease, or are taking any other medications.,You may feel warmth, tingling, or pain at the IV site; report any discomfort immediately.,Do not stop treatment abruptly without consulting your doctor.,Inform your provider if you develop muscle weakness, irregular heartbeat, or numbness.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium chloride provides a source of potassium ions, which are essential for maintaining intracellular tonicity, nerve impulse conduction, muscle contraction, and acid-base balance. Sodium chloride provides sodium and chloride ions, which are necessary for maintaining extracellular fluid volume and osmolality.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: Intravenous infusion: 0.037% potassium chloride in 0.9% sodium chloride solution; rate not to exceed 10 m Eq/hour (or 10 mmol/hour) potassium; typical adult dose 20-40 m Eq per day, adjusted based on serum potassium levels.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER: Potassium chloride is a normal constituent of body fluids and is essential for cellular function. At physiol. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.